In our previous studies on local therapies, HIFU and HS201-PDT, against BCs, we tested the combination strategy with PD-1/PD-L1 blockade and demonstrated that these local treatments combined with anti-PD-L1 antibodies could enhance induction of tumor-antigen-specific immune response and elicit strong antitumor activity, which suppressed the growth of distant tumors as well as directly treated tumors [13,22]. The gene discussed is CD274; the disease is neoplasm.